Inhibition of intrahepatic hepatitis B virus replication by antiviral drugs in a novel transgenic mouse model.

AUTOR(ES)

Nagahata, T

RESUMO

Transgenic mice which carry the integrated human hepatitis B virus (HBV) genome and produce HBV particles in the liver were treated with antiviral compounds, and the amount of viral DNA in the liver and serum was monitored by Southern analyses. Mouse alpha interferon (200,000 U per injection, twice daily for 3 days) and a novel nucleoside, oxetanocin G (15 mg/kg of body weight per injection, twice daily for 7 days), inhibited viral DNA synthesis in the liver almost completely. This animal model should prove useful in evaluating anti-HBV agents.

Documentos Relacionados

• Anti-Hepatitis B Virus Activity of ORI-9020, a Novel Phosphorothioate Dinucleotide, in a Transgenic Mouse Model
• Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model.
• Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid.
• Inhibition of Hepatitis B Virus Replication during Adenovirus and Cytomegalovirus Infections in Transgenic Mice†
• Inhibition of replication of hepatitis B virus by cytallene in vitro.